nach oben

Erschienen in:

01.08.2005 | Article

Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition

verfasst von: C. Wihler, S. Schäfer, K. Schmid, E. K. Deemer, G. Münch, M. Bleich, A. E. Busch, T. Dingermann, V. Somoza, J. W. Baynes, J. Huber

Erschienen in: Diabetologia | Ausgabe 8/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Renal accumulation of AGEs may contribute to the progression of diabetic nephropathy. We evaluated the effect of ramipril (a pure ACE inhibitor) and AVE7688 (a dual inhibitor of ACE and neutral endopeptidase) on renal accumulation of the advanced glycation end-product (AGE) 3-deoxyglucosone-imidazolone, carboxymethyllysine (CML) and pentosidine, and on clearance of CML in type 2 diabetes.

Methods

Male Zucker diabetic fatty rats (ZDF, Gmi-fa/fa) rats were treated from age 10 to 37 weeks with ramipril (1 mg·kg⁻¹·day⁻¹), AVE7688 (45 mg·kg⁻¹·day⁻¹) or without drug. Ramipril and AVE7688 reduced albuminuria by 30 and 90%, respectively.

Results

ZDF rats showed increased renal accumulation of the AGE subtypes 3-deoxyglucosone-imidazolone, pentosidine and CML by about 40, 55 and 55%, respectively compared with heterozygous, non-diabetic control animals at the age of 37 weeks. AVE7688 but not ramipril attenuated the renal accumulation of 3-deoxyglucosone-imidazolone, pentosidine and CML and improved CML clearance in ZDF rats. During glycation reactions in vitro, AVE7688 also demonstrated potent chelating activity and inhibited metal-catalysed formation of pentosidine and CML.

Conclusions/interpretation

Improved AGE clearance and direct inhibition of AGE formation by chelation may contribute to reduced accumulation of renal AGEs and to the nephroprotective effects of vasopeptidase inhibition in type 2 diabetes.

Cooper ME (2001) Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44:1957–1972CrossRefPubMed

Raj DS, Choudhury D, Welbourne TC, Levi M (2000) Advanced glycation end products: a nephrologist’s perspective. Am J Kidney Dis 35:365–380PubMed

Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223–234PubMed

Miyata T, Izuhara Y, Sakai H, Kurokawa K (1999) Carbonyl stress: increased carbonyl modification of tissue and cellular proteins in uremia. Perit Dial Int 19(Suppl 2):S58–S61PubMed

Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44:129–146PubMed

Heidland A, Sebekova K, Schinzel R (2001) Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38:S100–S106PubMed

Kislinger T, Fu C, Huber B et al (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMed

Bierhaus A, Schiekofer S, Schwaninger M et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50:2792–2808PubMed

Yeh CH, Sturgis L, Haidacher J et al (2001) Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50:1495–1504PubMed

10.

Schleicher ED, Bierhaus A, Haring HU, Nawroth PP, Lehmann R (2001) Chemistry and pathobiology of advanced glycation end products. Contrib Nephrol (131):1–9PubMed

11.

Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99:457PubMed

12.

Tanji N, Markowitz GS, Fu C et al (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11:1656–1666PubMed

13.

Kilhovd BK, Giardino I, Torjesen PA et al (2003) Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52:163–167PubMed

14.

Monnier VM, Sell DR, Nagaraj RH et al (1992) Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 41(Suppl 2):36–41PubMed

15.

HOPE Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259

16.

Forbes JM, Cooper ME, Thallas V et al (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274–3282PubMed

17.

Davis BJ, Johnston CI, Burrell LM et al (2003) Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 46:961–971PubMed

18.

Wenzel UO, Wolf G, Jacob I et al (2003) Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats. Nephrol Dial Transplant 18:2005–2013PubMed

19.

Schafer S, Linz W, Bube A et al (2003) Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res 60:447–454PubMed

20.

Drusch S, Faist V, Erbersdobler HF (1999) Determination of N(epsilon)-(carboxymethyl)lysine in milk products by a modified reversed-phase HPLC method. Food Chem 65:547–553

21.

Price DL, Rhett PM, Thorpe SR, Baynes JW (2001) Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276:48967–48972PubMed

22.

Schafer S, Linz W, Vollert H et al (2004) The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Diabetologia 47:98–103PubMed

23.

Forbes JM, Cooper ME, Oldfield MD, Thomas MC (2003) Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 14:S254–S258PubMed

24.

Niwa T, Katsuzaki T, Miyazaki S et al (1997) Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99:1272–1280PubMed

25.

Suzuki D, Miyata T, Saotome N et al (1999) Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10:822–832PubMed

26.

Wagner Z, Wittmann I, Mazak I et al (2001) N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis 38:785–791PubMed

27.

Koschinsky T, He CJ, Mitsuhashi T et al (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94:6474–6479PubMed

28.

Morcos M, Sayed AA, Bierhaus A et al (2002) Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51:3532–3544PubMed

29.

Thornalley PJ, Battah S, Ahmed N et al (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581–592PubMed

30.

Wilkinson-Berka JL, Kelly DJ, Koerner SM et al (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51:3283–3289PubMed

31.

Agardh CD, Stenram U, Torffvit O, Agardh E (2002) Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats. J Diabetes Its Complicat 16:395–400CrossRef

32.

Forbes JM, Soulis T, Thallas V et al (2001) Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108–114PubMed

33.

He C, Sabol J, Mitsuhashi T, Vlassara H (1999) Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48:1308–1315PubMed

34.

Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H (2000) The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 49:1030–1035PubMed

35.

Makita Z, Bucala R, Rayfield EJ et al (1994) Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519–1522PubMed

36.

Gugliucci A, Bendayan M (1996) Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39:149–160PubMed

37.

Sebekova K, Faist V, Hofmann T, Schinzel R, Heidland A (2003) Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. Am J Kidney Dis 41:S48–S51PubMed

38.

Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G (1996) Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50:627–634PubMed

39.

Thallas-Bonke V, Lindschau C, Rizkalla B et al (2004) Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53:2921–2930PubMed

40.

Linz W, Jessen T, Becker RHA, Scholkens BA, Wiemer G (1997) Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation 96:3164–3172PubMed

41.

Miyata T, van Ypersele de Strihou C, Ueda Y et al (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478–2487PubMed

42.

Nangaku M, Miyata T, Sada T et al (2003) Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14:1212–1222PubMed

43.

Saxena AK, Saxena P, Wu X, Obrenovich M, Weiss MF, Monnier VM (1999) Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 260:332–338PubMed

44.

Weiss MF, Erhard P, Kader-Attia FA et al (2000) Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 57:2571–2585PubMed

45.

Cooper GJS, Phillips ARJ, Choong SY et al (2004) Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53:2501–2508PubMed

Titel: Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition
verfasst von: C. Wihler
S. Schäfer
K. Schmid
E. K. Deemer
G. Münch
M. Bleich
A. E. Busch
T. Dingermann
V. Somoza
J. W. Baynes
J. Huber
Publikationsdatum: 01.08.2005
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 8/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-005-1837-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition